Cardinal Health (CAH)
(Delayed Data from NYSE)
$99.27 USD
+1.56 (1.60%)
Updated May 31, 2024 04:00 PM ET
After-Market: $99.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$99.27 USD
+1.56 (1.60%)
Updated May 31, 2024 04:00 PM ET
After-Market: $99.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Zacks News
Here's Why You Should Hold on to Masimo (MASI) Stock Now
by Zacks Equity Research
Masimo (MASI) raises 2019 revenue and EPS guidance.
Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco
by Zacks Equity Research
Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco
Here's Why You Should Retain PRA Health (PRAH) Stock Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, escalating direct costs remain a woe.
5 Excellent GARP Stocks With Discounted PEG
by Urmimala Biswas
PEG-based investing becomes more rewarding when other relevant parameters are considered.
Cooper Companies' CVI Unit Gets FDA Nod, To Boost Eye Health
by Zacks Equity Research
Cooper Companies' (COO) CVI Unit has receives FDA approval for its MiSight 1 day contact lens, which complements its commitment to eye health innovation.
Here's Why You Should Hold on to Becton, Dickinson Stock Now
by Zacks Equity Research
Becton, Dickinson (BDX) expects tariffs to impact its bottom line in first-quarter fiscal 2020.
Why Cardinal Health (CAH) Could Be a Top Value Stock Pick
by Zacks Equity Research
Cardinal Health (CAH) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Here's Why You Should Hold on to PerkinElmer Stock for Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
Here's Why You Should Hold Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
Is Deep Value ETF (DVP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DVP
Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal (CAH) delivered earnings and revenue surprises of 16.51% and 0.99%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Nov 7 Earnings Roster: ABC, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Why Earnings Season Could Be Great for Cardinal Health (CAH)
by Zacks Equity Research
Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Hanger (HNGR) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hanger (HNGR) Q3 performance is likely to have benefited from strong demand for Orthotic and Prosthetic services across the board.
Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
CVS Health's (CVS) Caremark legacy business is expected to have delivered a solid third quarter, backed by the company's robust execution of its formulary and cost-containment tools.
What's in the Cards for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) Q1 earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) expects to have gained from calcimimetics in the third quarter.
Can All-Line Growth Boost CVS Health's (CVS) Q3 Earnings?
by Zacks Equity Research
The newly-incorporated Health Care Benefits business already registers top-line contributions for CVS Health (CVS).
Cardinal Health (CAH) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Genetic Testing Drive Invitae's (NVTA) Q3 Earnings?
by Zacks Equity Research
Several bio-pharma partnerships and acquisitions are likely to have contributed to Invitae's (NVTA) top line in Q3.
Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?
by Zacks Equity Research
The robust performance of the Primescan system in Europe and the United States is expected to have contributed to Henry Schein's (HSIC) top line during Q3.
Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?
by Zacks Equity Research
Headwinds in the DCB business and unfavorable foreign exchange rates might have partially impacted Becton, Dickinson's (BDX) fiscal Q4 performance.
What's in Store for Tandem Diabetes' (TNDM) Q3 Earnings?
by Zacks Equity Research
Growth in t:slim X2 insulin pump sales is expected to get reflected in Tandem Diabetes' (TNDM) upcoming quarterly results.
PerkinElmer (PKI) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q3 earnings. However, forex is likely to have been a dampener.